All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-000362-12 | A Double-Blind, Randomised, Dose-Ranging Study to Compare K-832 with Placebo in the treatment of Patients with Active Rheumatoid Arthritis | bad-data | |
| Reported results | 2004-002090-23 | A phase IIa multicentre randomised double-blind, double-dummy study to evaluate the efficacy and safety of K-111 versus Fenofibrate in patients with hyperlipidaemia. | 2005-10-17 | due-trials |
| Reported results | 2005-001000-39 | STUDY OF PITAVASTATIN 2 MG vs. ATORVASTATIN 10 MG AND PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA | 2006-11-08 | due-trials |
| Reported results | 2005-001033-15 | STUDY OF PITAVASTATIN 2 MG vs. SIMVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG FOLLOWING UP-TITRATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA | 2006-09-29 | due-trials |
| Reported results | 2005-001037-15 | STUDY OF PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP- TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA AND 2 OR MORE RISK FACTORS FOR CORONARY HEART DISEASE | 2006-10-02 | due-trials |
| Reported results | 2005-001038-34 | STUDY OF PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPIDEMIA | 2007-09-12 | due-trials |
| Reported results | 2005-001039-31 | STUDY OF PITAVASTATIN 1 MG vs. PRAVASTATIN 10 MG, PITAVASTATIN 2 MG vs. PRAVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. PRAVASTATIN 40 MG (FOLLOWING UP-TITRATION) IN ELDERLY PATIENTS WITH PRIMARY HYPERCHO... | 2006-05-12 | due-trials |
| Reported results | 2005-001112-41 | OPEN-LABEL, LONG TERM 1 YEAR EXTENSION STUDY OF PITAVASTATIN 4MG QD IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA | 2007-11-26 | due-trials |
| Reported results | 2005-005980-27 | OPEN-LABEL, LONG-TERM ( ≥ 1 YEAR) EXTENSION STUDY OF PITAVASTATIN 2 MG AND 4 MG QD IN ELDERLY PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA | 2007-12-19 | due-trials |
| Reported results | 2005-005981-35 | DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS SIMVASTATIN (40 MG AND 80 MG), WITH A SINGLE-BLIND EXTENSION OF TREATMENT, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPID... | 2007-08-14 | due-trials |
| Reported results | 2005-006041-16 | DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS ATORVASTATIN (20 MG AND 40 MG), WITH A SINGLE BLIND EXTENSION OF TREATMENT IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPIDEM... | 2008-04-29 | due-trials |
| Reported results | 2011-004964-32 | A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011 Studio doppio cieco, rando... | 2013-06-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-004983-32 | A 52-Week Open-Label Extension and Safety Study of Pitavastatin in High- Risk Hyperlipidaemia in Childhood, P/266/2011, P/267/2011, P/268/2011 Studio sull'estensione in aperto a 52 settimane e sul... | 2014-06-10 | bad-data |
| Reported results | 2013-001517-32 | A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels | 2014-09-23 | due-trials |
| Reported results | 2015-003511-37 | A Phase 3, Multi-Center, Placebo-Controlled, Randomized, DoubleBlind, 12-Week Study With a 40-Week, Active-Controlled, DoubleBlind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Pat... | 2019-06-24 | due-trials |
| Reported results | 2016-001518-39 | A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patie... | 2019-07-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003818-26 | Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT) | 2022-07-27 | bad-data |
| Not reported | 2019-003280-22 | A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12-Week, Phase 2 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Patients with Fuc... | 2022-06-27 | due-trials |
| Other | 2021-003901-23 | A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nona... | not-yet-due | |
| Other | 2021-006456-14 | A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and... | not-yet-due |